| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 564457000 | Plural alicyclic rings | 7 |
| 564458000 | Polycyclo ring system | 7 |
| 564459000 | Tricyclo ring system | 6 |
| 20110282100 | PROCESS FOR PREPARING MEMANTINE - The present invention relates to a process for preparing memantine, or a pharmaceutically acceptable salt thereof (e.g., memantine hydrochloride), which is substantially free of impurities. | 11-17-2011 |
| 20110288336 | METHOD FOR PRODUCING MEMANTINE - Method for producing 1-amino-3,5-dimethyladamantane or a salt thereof, comprising: (i) heating 1-formamido-3,5-dimethyladamantane with a base in a protic solvent. | 11-24-2011 |
| 20110306796 | PROCESS FOR THE PREPARATION OF 1-BROMO-3,5-DIMETHYL ADAMANTANE - The present invention relates to an improved process for the preparation of 1-bromo-3,5-dimethyl adamantane of formula (III), which is an useful intermediate for synthesis of 1-amino-3,5-dimethyl adamantane of formula (I) or pharmaceutically acceptable salt thereof. | 12-15-2011 |
| 20120010431 | METHOD FOR PRODUCING 1-ADAMANTYL TRIMETHYLAMMONIUM HYDROXIDE - The present invention relates to a process for preparing 1-adamantyltrimethyl-ammonium hydroxide. | 01-12-2012 |
| 20120264978 | COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
| 20150368183 | MANUFACTURING PROCESS FOR MEMANTINE - A method for manufacturing 3,5-dimethyl-1-adamantanamine of the present invention comprises: (i) a step of reacting 3,5-dimethyl-1-adamantanol with an acid and nitrile in an organic solvent to obtain a reaction solution; (ii) a step of adding water to the reaction solution obtained in step (i) to obtain 1-amido-3,5-dimethyladamantane; and (iii) a step of hydrolyzing 1-amido-3,5-dimethyladamantane obtained in step (ii) in the presence of an alcohol-containing solvent and an inorganic base. | 12-24-2015 |
| 564460000 | Bicyclo ring system | 1 |
| 20140135529 | METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine xconcentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. | 05-15-2014 |
